1. Association between chromosomal aberration of exfoliated bladder cells in the urine and oxidative stress in patients with bladder transitional cell carcinoma
   Dong Wang et al, 2017, Oncology Letters CrossRef
2. Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis
   Xiaoning Gan et al, 2016, Disease Markers CrossRef
3. Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma
   Huili Ren et al, 2022, Frontiers in Genetics CrossRef
4. Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer
   Xiaohong Pu et al, 2018, Medicine CrossRef
5. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies
   Francesco Massari et al, 2015, Critical Reviews in Oncology/Hematology CrossRef
6. Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer
   Shiqi Li et al, 2016, Oncotarget CrossRef
7. Tp53 and its potential therapeutic role as a target in bladder cancer
   Chiara Ciccarese et al, 2017, Expert Opinion on Therapeutic Targets CrossRef
8. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
   Danijel Sikic et al, 2021, Cancer Management and Research CrossRef
9. PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest
   Li Huang et al, 2015, Oncotarget CrossRef
10. p16 gene silencing along with p53 single-nucleotide polymorphism and risk of esophageal cancer in Northeast India
    Mandakini Das et al, 2017, Tumor Biology CrossRef
11. Follicular dendritic cell sarcoma (FDCS) of urinary bladder with coexisting urothelial carcinoma–a case report
    Jing Sun et al, 2019, BMC Urology CrossRef
12. Targeting Hsp90 in urothelial carcinoma
    Mahmoud Chehab et al, 2015, Oncotarget CrossRef
13. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma
    Johannes Breyer et al, 2018, Clinical Genitourinary Cancer CrossRef
14. The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review
    David Casadevall et al, 2017, Cancer Treatment Reviews CrossRef
15. Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up
    Yanling Wang et al, 2019, Medical Oncology CrossRef
16. The relationship between P16INK4A and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand
    Arisara Poosari et al, 2022, Scientific Reports CrossRef
17. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II α , survivin, and E-cadherin
    Maria Rosaria Raspollini et al, 2016, Human Pathology CrossRef